What is NDC 62332-711?

62332-711 is the product NDC for Methotrexate, Methotrexate sodium 25 mg/mL injection, solution, listed with the FDA by Alembic Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Alembic Pharmaceuticals Inc., NDC labeler code 62332. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Methotrexate?

51 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Methotrexate NDC 62332-711 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62332-711Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62332-0711Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62332-711-05	6233207110562332071105	5 VIAL, MULTI-DOSE in 1 CARTON (62332-711-05) / 2 mL in 1 VIAL, MULTI-DOSE (62332-711-01)Marketed from Apr 15, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methotrexate
Generic name (nonproprietary): methotrexate
Active ingredients: Methotrexate sodium — 25 mg/mL
Dosage form: Injection, Solution
Route: Intramuscular, Intravenous, Subcutaneous
Labeler: Alembic Pharmaceuticals Inc.NDC labeler code 62332
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220225
Marketing start: Apr 15, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Folic Acid Metabolism Inhibitors (Mechanism)
Identifiers: Product ID 62332-711_91ce9c78-370f-49a1-ae22-428bdddb389fSPL ID 91ce9c78-370f-49a1-ae22-428bdddb389fSPL set ID a63364d5-4dfa-49d7-8a5e-c8959ae1d37aRxCUI 1655956, 1946772UNII 3IG1E710ZN
Pharmacologic class: Folate Analog Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N462332071105 followed by a unit qualifier and the quantity

Package 62332-0711-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 16, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Methotrexate Injection is a folate analog metabolic inhibitor indicated for: The following neoplastic diseases for the: Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) Treatment of adults with squamous cell carcinoma of the head and neck as…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62332-711

What is NDC 62332-711?: 62332-711 is the product NDC for Methotrexate, Methotrexate sodium 25 mg/mL injection, solution, listed with the FDA by Alembic Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Methotrexate.
What is the active ingredient?: Methotrexate sodium.
Who is the labeler?: Alembic Pharmaceuticals Inc., NDC labeler code 62332. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Methotrexate?: 51 other product NDCs are listed under this name. See all Methotrexate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Methotrexate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Methotrexate	Methotrexate 2.5 mg/1	TabletOral	American Health Packaging	60687-975	60687-0975-94
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-711	46708-0711-05
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-712	46708-0712-01
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Inc.	62332-712	62332-0712-01
Methotrexate	Methotrexate 2.5 mg/1	TabletOral	AvPAK	50268-554	50268-0554-15
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Safecor Health LLC	48433-065	48433-0065-05
Methotrexate	Methotrexate sodium 2.5 mg/1	TabletOral	Coupler LLC	67046-1524	67046-1524-03
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Hospira, Inc.	61703-161	61703-0161-05
Methotrexate	Methotrexate sodium 50 mg/2mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Eugia US LLC	55150-510	55150-0510-0155150-0510-05
Methotrexate	Methotrexate sodium 100 mg/4mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Eugia US LLC	55150-511	55150-0511-0155150-0511-10

All 52 Methotrexate NDCs

Other NDCs under ANDA 220225

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220225
Product	Strength	Form · route	Labeler	Product NDC
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-711
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Limited	46708-712
Methotrexate	Methotrexate sodium 25 mg/mL	Injection, SolutionIntramuscular, Intrathecal, Intravenous, Subcutaneous	Alembic Pharmaceuticals Inc.	62332-712